DBV Technologies: VITESSE Delivers Positive Results, THRIVE Presented at EAACI
DBV Technologies announced on Monday new positive data from its phase 3 VITESSE study and introduced the protocol of its phase 2 THRIVE study, both focusing on its epicutaneous immunotherapy patch for children and infants allergic to peanuts. These studies will be presented at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Congress, to be held from June 12 to 15 in Istanbul.
VITESSE Study Shows Significant Efficacy in Children with Atopic Comorbidities
The Viaskin Peanut patch demonstrated statistically significant efficacy compared to placebo in children aged 4 to 7 years with peanut allergies associated with other common atopic conditions. The VITESSE study randomized 654 participants (438 treated with the patch, 216 receiving a placebo). After 12 months, response rates in the treated group reached 48.3% in children suffering from asthma, 46.8% in those with concurrent food allergies, and 47.2% in those with atopic dermatitis, compared to 19.6%, 13.6%, and 13.2% respectively in the placebo groups. These results are comparable to the overall response rate of the study, which was 46.6% for the active treatment against 14.9% for the placebo.
THRIVE: A New Study in Infants Aged 6 to 12 Months
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
DBV Technologies has initiated the phase 2 THRIVE study, which will recruit approximately 250 infants aged 6 to 12 months with confirmed peanut allergies. This study will assess the efficacy and safety of the Viaskin Peanut patch aimed at enabling unrestricted peanut consumption after three years of treatment. Daniel Tassé, CEO of DBV Technologies, stated that these two presentations highlight 'the versatility and clinical interest of the Viaskin Peanut patch program across different patient populations.' The company asserts that the results of VITESSE 'reinforce our confidence in the potential clinical value of the Viaskin Peanut patch.'
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1M€dedollars
Net income: -47,6M€dedollars
Free cash flow: -49M€dedollars
Guidance from the release
Toute l'équipe de DBV démontre une focalisation et une rigueur exceptionnelles alors que nous abordons des étapes décisives au cours des prochains mois.
Risks mentioned
Augmentation significative des dépenses de R&D.
Perte nette en hausse à 47,6 millions de dollars.
Opportunities identified
Dépôt de la demande de licence biologique prévu pour 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
